Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...
When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...
With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback